Skip to ContentSkip to Navigation
How to find us dr. K. Damman

Research interests

Kevin Damman is clinical cardiologist and head of the heart transplant and left ventricular assist device program at the University Medical Center Groningen. His research focuses on acute and advanced heart failure, with particular emphasis on the cardiorenal axis. Current research interests are focused on improving treatment of acute heart failure patients, including early assessment of effect of decongestive therapies, SGLT2-inhibition in (acute) heart failure and the role of the kidney in the process of cardiorenal interaction. He is principle investigator of the EMPA-RESPONSE-AHF study  on empagliflozin in acute heart failure and is part of the steering committee of the ADVOR trial investigating acetazolamide in acute heart failure. Dr Damman is associate editor of the European Journal of Heart Failure and serves as official European Society of Cardiology (ESC) Journals Twitter editor. Furthermore, he is member of the working groups on Cardiorenal Dysfunction and Acute Heart Failure from the Heart Failure Association of the ESC.


Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)

Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology

Clinical importance of urinary sodium excretion in acute heart failure

Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment

Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction

Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial

Spironolactone: diuretic or disease-modifying drug in heart failure with preserved ejection fraction?

The Effect of Decongestion on Intrarenal Venous Flow Patterns in Patients With Acute Heart Failure

Read more